PH26334A - A process for the preparation of 2-[2-[4-[(4 chloro phenyl) phenyl methyl]-1-piperazinyl]ethoxy]-acetic and its dihydrochloride - Google Patents

A process for the preparation of 2-[2-[4-[(4 chloro phenyl) phenyl methyl]-1-piperazinyl]ethoxy]-acetic and its dihydrochloride Download PDF

Info

Publication number: PH26334A
Authority: PH; Philippines
Prior art keywords: chlorophenyl; phenylmethyl; piperazinyl; dihydrochloride; ethoxy
Prior art date: 1988-11-23

Application number

PH39569A

Other languages

English (en)

Inventor

Guy Bodson

Eric Cossement

Jean Gobert

Original Assignee

Ucb Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-11-23

Filing date

1989-11-23

Publication date

1992-04-29

1989-11-23 Application filed by Ucb Sa filed Critical Ucb Sa

1992-04-29 Publication of PH26334A publication Critical patent/PH26334A/en

Links

125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title claims description 29
238000000034 method Methods 0.000 title claims description 12
238000002360 preparation method Methods 0.000 title claims description 6
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 title description 23
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 13
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 10
229910052783 alkali metal Inorganic materials 0.000 claims description 10
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 9
FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 claims description 9
150000001340 alkali metals Chemical class 0.000 claims description 8
125000000068 chlorophenyl group Chemical group 0.000 claims description 7
ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 6
-1 alkali metal salt Chemical class 0.000 claims description 3
239000000376 reactant Substances 0.000 claims description 3
239000012429 reaction media Substances 0.000 claims description 3
159000000000 sodium salts Chemical class 0.000 claims description 2
230000003247 decreasing effect Effects 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
239000000203 mixture Substances 0.000 description 8
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
229960000443 hydrochloric acid Drugs 0.000 description 5
235000011167 hydrochloric acid Nutrition 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
ZJQSBXXYLQGZBR-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethanol Chemical compound C1CN(CCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZJQSBXXYLQGZBR-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
229960001803 cetirizine Drugs 0.000 description 3
125000004193 piperazinyl group Chemical group 0.000 description 3
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
229940089960 chloroacetate Drugs 0.000 description 2
FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 2
238000004821 distillation Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
238000004064 recycling Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
UZKBSZSTDQSMDR-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]piperazine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)N1CCNCC1 UZKBSZSTDQSMDR-UHFFFAOYSA-N 0.000 description 1
ALKWTKGPKKAZMN-UHFFFAOYSA-N 1-chloro-4-[chloro(phenyl)methyl]benzene Chemical compound C=1C=C(Cl)C=CC=1C(Cl)C1=CC=CC=C1 ALKWTKGPKKAZMN-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
239000003513 alkali Substances 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003849 aromatic solvent Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
208000024998 atopic conjunctivitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
RDFIZBYHUOHTQI-UHFFFAOYSA-N methyl 2-(2-chloroethoxy)acetate Chemical compound COC(=O)COCCCl RDFIZBYHUOHTQI-UHFFFAOYSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
150000007530 organic bases Chemical group 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
229960005235 piperonyl butoxide Drugs 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PH39569A 1988-11-23 1989-11-23 A process for the preparation of 2-[2-[4-[(4 chloro phenyl) phenyl methyl]-1-piperazinyl]ethoxy]-acetic and its dihydrochloride PH26334A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB888827390A GB8827390D0 (en)	1988-11-23	1988-11-23	Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride

Publications (1)

Publication Number	Publication Date
PH26334A true PH26334A (en)	1992-04-29

Family

ID=10647346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH39569A PH26334A (en)	1988-11-23	1989-11-23	A process for the preparation of 2-[2-[4-[(4 chloro phenyl) phenyl methyl]-1-piperazinyl]ethoxy]-acetic and its dihydrochloride

Country Status (17)

Country	Link
KR (1)	KR970009727B1 (de)
AT (1)	AT398970B (de)
CA (1)	CA1320732C (de)
CY (1)	CY1696A (de)
DK (1)	DK174289B1 (de)
ES (1)	ES2018967A6 (de)
FI (1)	FI91861C (de)
GB (2)	GB8827390D0 (de)
GR (1)	GR1000576B (de)
HK (1)	HK45493A (de)
HU (1)	HU208002B (de)
NO (1)	NO172287C (de)
PH (1)	PH26334A (de)
PL (1)	PL161374B1 (de)
PT (1)	PT92363B (de)
RU (1)	RU1838306C (de)
SG (1)	SG12793G (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2122042T3 (es) *	1992-09-24	1998-12-16	Sepracor Inc	Tratamiento de rinitis alergica y asma que emplea (-)cetirizina.
ES2128556T3 (es) *	1992-09-24	1999-05-16	Sepracor Inc	Tratamiento transdermico de la urticaria usando (+)-cetirizina opticamente pura.
BE1010094A3 (fr) *	1996-04-10	1997-12-02	Ucb Sa	Nouveaux [2-(1-piperazinyl)ethoxy] methyle substitues.
BE1010095A3 (fr) *	1996-04-10	1997-12-02	Ucb Sa	Procede de preparation de l'acide 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl] ethoxy]-acetique et de ses sels.
CA2180993A1 (en) *	1996-07-11	1998-01-12	Yong Tao	Methods for the manufacture of cetirizine
EP0919550A1 (de) *	1997-11-26	1999-06-02	Ucb, S.A.	Pseudopolymorphische Formen der 2-2-4-Bis(4-fluorophenyl)methyl-1-piperazinyl-ethoxyessigsäure Dihydrochloride
IL124195A (en) *	1998-04-23	2000-08-31	Chemagis Ltd	Process for the preparation of esters of 2-¬4-¬4-chlorophenyl¾phenylmethyl¾-1-piperazinyl¬ethoxy¾acetic acid
DK176706B1 (da) *	1999-03-04	2009-03-30	Sandoz As	Fremgangsmåde til fremstilling af 2-{2-[4-(diphenylmethyl)-1-piperazinyl]ethoxy}-eddikesyre-forbindelser eller salte deraf
US6265579B1 (en) *	1999-10-29	2001-07-24	Salsbury Chemicals, Inc.	Process for preparing piperazine-substituted aliphatic carboxylates
US7199241B1 (en)	2001-05-29	2007-04-03	Ucb, S.A.	Process for preparing (S) and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide
US6977301B1 (en)	2001-05-29	2005-12-20	Ucb, S.A.	Process for preparing (S) and (R)—2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide
WO2003104212A1 (en) *	2002-06-05	2003-12-18	Dr.Reddy's Laboratories Ltd.	A novel amorphous form of [2-[4-[(4-chlorophenyl)-phenyl methyl]-1- piperazinyl] ethoxy] acetic acid dihydrochloride (cetirizine dihydrochloride)
US7381821B2 (en)	2003-01-23	2008-06-03	Ucb, S.A.	Piperazine derivatives and their use as synthesis intermediates
AU2003228011A1 (en) *	2003-05-21	2004-12-13	Wockhardt Limited	2-(2-(4-((4-chlorophenyl) phenylmethyl)-1-piperazinyl)ethoxy)acetic acid monohydrochloride as anti-allergenic compound and process for its production
WO2010046908A2 (en)	2008-09-17	2010-04-29	Calyx Chemicals And Pharmaceuticals Pvt. Ltd.	Novel water based process for the preparation of substituted diphenylmethyl piperazines
KR101418404B1 (ko)	2012-01-06	2014-07-10	한미약품 주식회사	레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
KR102226833B1 (ko)	2013-06-28	2021-03-12	한미약품 주식회사	레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB817231A (en) *	1956-01-27	1959-07-29	Henri Morren	New derivatives of n-mono-benzhydryl-piperazine and process for the preparation thereof
US3090725A (en) *	1960-02-29	1963-05-21	Burroughs Wellcome Co	Phosphorylated quaternary ammonium compounds of improved oral absorption
FI75816C (fi) *	1981-02-06	1988-08-08	Ucb Sa	Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.

1988
- 1988-11-23 GB GB888827390A patent/GB8827390D0/en active Pending
1989
- 1989-09-29 CA CA000614708A patent/CA1320732C/en not_active Expired - Fee Related
- 1989-11-20 GR GR890100771A patent/GR1000576B/el not_active IP Right Cessation
- 1989-11-21 PT PT92363A patent/PT92363B/pt not_active IP Right Cessation
- 1989-11-21 GB GB8926242A patent/GB2225320B/en not_active Expired - Lifetime
- 1989-11-22 PL PL1989282411A patent/PL161374B1/pl unknown
- 1989-11-22 NO NO894650A patent/NO172287C/no not_active IP Right Cessation
- 1989-11-22 FI FI895563A patent/FI91861C/fi not_active IP Right Cessation
- 1989-11-22 DK DK198905865A patent/DK174289B1/da not_active IP Right Cessation
- 1989-11-22 ES ES8903974A patent/ES2018967A6/es not_active Expired - Lifetime
- 1989-11-22 AT AT0266489A patent/AT398970B/de not_active IP Right Cessation
- 1989-11-22 RU SU894742406A patent/RU1838306C/ru active
- 1989-11-22 HU HU896130A patent/HU208002B/hu not_active IP Right Cessation
- 1989-11-23 PH PH39569A patent/PH26334A/en unknown
- 1989-11-23 KR KR1019890017039A patent/KR970009727B1/ko not_active Expired - Fee Related
1993
- 1993-02-06 SG SG127/93A patent/SG12793G/en unknown
- 1993-05-13 HK HK454/93A patent/HK45493A/xx not_active IP Right Cessation
1994
- 1994-01-14 CY CY160694A patent/CY1696A/en unknown

Also Published As

Publication number	Publication date
RU1838306C (ru)	1993-08-30
NO172287B (no)	1993-03-22
PT92363A (pt)	1990-05-31
NO894650D0 (no)	1989-11-22
SG12793G (en)	1993-04-16
PL161374B1 (pl)	1993-06-30
AT398970B (de)	1995-02-27
NO172287C (no)	1993-06-30
KR970009727B1 (ko)	1997-06-17
CA1320732C (en)	1993-07-27
FI91861C (fi)	1994-08-25
DK586589D0 (da)	1989-11-22
PT92363B (pt)	1995-07-18
DK586589A (da)	1990-05-24
HUT53626A (en)	1990-11-28
HU208002B (en)	1993-07-28
FI895563A0 (fi)	1989-11-22
CY1696A (en)	1994-01-14
GR890100771A (en)	1990-12-31
HU896130D0 (en)	1990-02-28
GB2225320B (en)	1992-09-02
NO894650L (no)	1990-05-25
DK174289B1 (da)	2002-11-18
GB2225320A (en)	1990-05-30
KR900007824A (ko)	1990-06-02
FI91861B (fi)	1994-05-13
ATA266489A (de)	1994-07-15
ES2018967A6 (es)	1991-05-16
GR1000576B (el)	1992-08-26
HK45493A (en)	1993-05-21
GB8827390D0 (en)	1988-12-29
GB8926242D0 (en)	1990-01-10

Publication	Publication Date	Title
PH26334A (en)	1992-04-29	A process for the preparation of 2-[2-[4-[(4 chloro phenyl) phenyl methyl]-1-piperazinyl]ethoxy]-acetic and its dihydrochloride
CA1317300C (en)	1993-05-04	Process for the preparation of 2-¬2-¬4-¬(4-chlorophenyl) phenylmethyl\|-1-piperazinyl\|ethoxy\|-acetic acid and its dihydrochloride
DK147421B (da)	1984-07-30	Analogifremgangsmaade til fremstilling af piperazinderivater eller syreadditionssalte eller kvaternaere ammoniumsalte deraf
US3337554A (en)	1967-08-22	Piperazino and homopiperazino-10-11-dihydrobenzo[b, f]-thiepin
JP6884857B2 (ja)	2021-06-09	フェニルアラニン類化合物の製造方法
EP1971585B1 (de)	2011-03-09	Verfahren zur herstellung eines pharmazeutischen zwischenprodukts
CN110950818B (zh)	2021-12-28	顺式-2,6-二甲基吗啉的纯化方法
US20130090475A1 (en)	2013-04-11	Process for the Preparation of Ranolazine
CA1041098A (en)	1978-10-24	1-(3-(naphthyl-1-yl-oxy)-propyl)-piperazine derivatives
US3654271A (en)	1972-04-04	Process for preparing simple and substituted morpholines
JP3911302B2 (ja)	2007-05-09	光学活性２−メチルピペラジンの製造法
FR2511246A1 (fr)	1983-02-18	Nouveaux alpha-aminoderives cycliques du 1-(3',4'-methylene-dioxyphenyl)ethanol et procede de fabrication
CA1193601A (en)	1985-09-17	Indanone-oxyalkyl-piperazine derivatives, their preparation, and pharmaceutical formulations containing these compounds
SU126886A1 (de)
JPS6216446A (ja)	1987-01-24	光学活性２−（４−ヒドロキシフエノキシ）プロピオン酸の製造方法
KR870000865B1 (ko)	1987-04-30	치환 안식향산 유도체의 제조방법
JPH0625158B2 (ja)	1994-04-06	１−（２−ピリミジル）ピペラジン類の製造法
NO167975B (no)	1991-09-23	Analogifremgangsmaate for fremstilling av terapeutisk aktive aminopropanolderivater av 3-(3-hydroksyfenyl)-1-propanonforbindelser.
SE178089C1 (de)	1961-01-01
JPS6025989A (ja)	1985-02-08	フルフリルアルコ−ル誘導体の製造方法
DK145911B (da)	1983-04-11	Fremgangsmaade til fremstilling af substituerede 3,4,5-trimethoxy-cinnamoylforbindelser
PL162803B1 (en)	1994-01-31	Method of synthesis of 2,4-di-/1,1-dimethylphenoxyacetic acid